One of the biggest shortcomings in cancer treatment is the inability, in many cases, to find and attack cancer cells that survive traditional chemotherapy. Biopharma has thrown a variety of weapons at the enemy, from combination regimens to targeted drugs, but with the need still evident, Vivolux AB is taking another approach: eliminating the stray cells by cutting off their power supply.